Drug class profile · refreshed daily from federal data

Central Nervous System Stimulant

14 molecules in this class, $296.7M combined CY2024 Part D spend across 2.3M claims. Class-level guide below for benefits decision-makers: where the money lives, where the savings live.

Last updated 14 Jul 2026

NADAC: weekly (every Wed)Part D Formulary: quarterlyPart D Spend: annualOrange Book: weeklyShortages: daily

Class summary at a glance.

Every drug in the Central Nervous System Stimulant class tracked across NADAC, Part D Formulary, Part D Spending, FDA Orange Book, and shortage data. Ranked below by CY24 Part D spend. Click any molecule for the full drug profile.

Molecules in class: 14tracked in Part D
CY24 Part D spend: $296.7Mcombined across class
Total Rx claims: 2.3M506K unique beneficiaries
Generic mfrs (active): 90across all molecules

Every drug in this class, ranked by Part D spend.

CY2024 dataCMS Part D Spending Dashboard

Lisdexamfetamine Dimesylate

Brand: Vyvanse · 633K Part D claims (CY24) · 156K beneficiaries · First FDA approval: 2007-02-23

18 generic mfrs 196 plans require PA Active FDA shortage

Low NADAC$2.81

→

Avg plan cost$4.07

Part D spend $186.8M 1× spread, current vs floor

Class share

63%

of class CY24 spend

View profile →

Methylphenidate

Brand: APTENSIO XR · 1.4M Part D claims (CY24) · 292K beneficiaries · First FDA approval: 1955-12-31

28 generic mfrs 882 plans require PA Active FDA shortage

Low NADAC$0.079

→

Avg plan cost$4.08

Part D spend $81.8M 52× spread, current vs floor

Class share

28%

of class CY24 spend

View profile →

Dextroamphetamine

Brand: DEXEDRINE · 145K Part D claims (CY24) · 29K beneficiaries · First FDA approval: 1976-08-02

11 generic mfrs 7 plans require PA

Low NADAC$0.349

→

Avg plan cost$3.72

Part D spend $15.3M 11× spread, current vs floor

Class share

of class CY24 spend

View profile →

Dexmethylphenidate

Brand: Focalin · 122K Part D claims (CY24) · 28K beneficiaries · First FDA approval: 2001-11-30

13 generic mfrs 311 plans require PA

Low NADAC$0.189

→

Avg plan cost$2.17

Part D spend $9.7M 11× spread, current vs floor

Class share

of class CY24 spend

View profile →

Amphetamine

Brand: Adzenys XR-ODT · 7K Part D claims (CY24) · 2K beneficiaries · First FDA approval: 2015-10-01

12 generic mfrs 8 plans require PA Active FDA shortage

Low NADAC$0.358

→

Avg plan cost$10.48

Part D spend $3.0M 29× spread, current vs floor

Class share

of class CY24 spend

View profile →

Acetaminophen, Caffeine, Dihydrocodeine Bitartrate

Brand: Trezix · — Part D claims (CY24) · First FDA approval: 2014-12-01

Brand-only (no generics)

Low NADAC—

→

Avg plan cost—

Part D spend —

Class share

of class CY24 spend

View profile →

Amphetamine Extended-Release

— Part D claims (CY24) · First FDA approval: 2025-09-01

Brand-only (no generics)

Low NADAC$15.95

→

Avg plan cost$16.19

Part D spend — 1× spread, current vs floor

Class share

of class CY24 spend

View profile →

Caffeine

Brand: CAFCIT · — Part D claims (CY24) · First FDA approval: 2006-09-21

6 generic mfrs

Low NADAC—

→

Avg plan cost—

Part D spend —

Class share

of class CY24 spend

View profile →

Caffeine and Sodium

— Part D claims (CY24) · First FDA approval: 1993-02-01

Brand-only (no generics)

Low NADAC—

→

Avg plan cost—

Part D spend —

Class share

of class CY24 spend

View profile →

Dextroamphetamine Saccharate, Amphetamine Aspartate Monohydrate, Dextroamphetamine Sulfate, and Amphetamine

Brand: Dextroamphetamine Saccharate, Amphetamine Aspartate Monohydrate, Dextroamphetamine Sulfate and Amphetamine Sulfate · — Part D claims (CY24) · First FDA approval: 2009-04-02

Brand-only (no generics) Active FDA shortage

Low NADAC$0.236

→

Avg plan cost$1.24

Part D spend — 5× spread, current vs floor

Class share

of class CY24 spend

View profile →

Dextroamphetamine Saccharate, Amphetamine Aspartate Monohydrate, Dextroamphetamine and Amphetamine

— Part D claims (CY24) · First FDA approval: 2002-06-14

Brand-only (no generics) 65 plans require PA

Low NADAC$0.236